Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Standard Dose
2.5MG;850MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 208473 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 2.5MG;850MG Sponsor PRINSTON PHARMA INC Submission history Latest submission status date: 2022-04-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 208473 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 2.5MG;850MG Sponsor PRINSTON PHARMA INC Submission history Latest submission status date: 2022-04-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.